Kestra Medical CFO exercises options, sells 79,500 shares

The scheduled transactions were made under a Rule 10b5-1 trading plan adopted November 5, 2025, and the sale prices were reported as weighted averages.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) Chief Financial Officer Vaseem Mahboob exercised options for 79,500 common shares at $17 per share across October 27 through October 29, 2026, then sold the same number of shares. Weighted-average sale prices were $30.0435 on October 27, $30.4815 on October 28 and $30.5979 on October 29. The scheduled exercise-and-sale transactions were made under a Rule 10b5-1 trading plan adopted November 5, 2025.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Mahboob Vaseem

Role Chief Financial Officer

Sold 79,500 shs ($2.41M)

Approx. gross sale proceeds $2.41M

Approx. exercise cost $1.35M

Type	Security	Shares	Price	Value
Exercise	Options ^F7	4,788	$0.00	$0.00
Exercise	Common Shares ^{F1, F2}	4,788	$17.00	$81K
Sale	Common Shares ^{F1, F4}	4,788	$30.5979	$147K
Exercise	Options ^F6	39,903	$0.00	$0.00
Exercise	Common Shares ^{F1, F2}	39,903	$17.00	$678K
Sale	Common Shares ^{F1, F3}	39,903	$30.4815	$1.22M
Exercise	Options ^F5	34,809	$0.00	$0.00
Exercise	Common Shares ^F1	34,809	$17.00	$592K
Sale	Common Shares ^{F1, F2}	34,809	$30.0435	$1.05M

Holdings After Transaction: Options — 79,500 contracts (Direct); Common Shares — 60,609 shares (Direct)

Footnotes (7)

F1. This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.
F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0100 to $30.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.3500 to $31.0400. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F5. Includes 91,066 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.
F6. Includes 51,163 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.
F7. Includes 46,375 fully vested options as of the filing date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

Key Figures

Shares exercised and sold: 34,809 shares Shares exercised and sold: 39,903 shares Shares exercised and sold: 4,788 shares +5 more

8 metrics

Shares exercised and sold 34,809 shares October 27, 2026

Shares exercised and sold 39,903 shares October 28, 2026

Shares exercised and sold 4,788 shares October 29, 2026

Exercise price $17 per share Options exercised October 27 through October 29, 2026

Weighted-average sale price $30.0435 per share October 27, 2026

Weighted-average sale price $30.4815 per share October 28, 2026

Weighted-average sale price $30.5979 per share October 29, 2026

Options vesting 33,125 options Vesting in equal monthly installments through March 6, 2027

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested options, equal monthly installments

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested options financial

"91,066 fully vested options as of the transaction date"

equal monthly installments financial

"remaining 33,125 options vesting in equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KMTS shares did the CFO exercise and sell?

Vaseem Mahboob, KMTS's chief financial officer, exercised options for and sold 79,500 common shares in three same-day sequences from October 27 through October 29, 2026: 34,809, 39,903 and 4,788 shares, respectively. Each exercise price was $17 per share; the sales were under a Rule 10b5-1 trading plan adopted November 5, 2025.

What were the sale prices for the KMTS shares?

The weighted-average sale prices were $30.0435 per share on October 27, 2026; $30.4815 on October 28, 2026; and $30.5979 on October 29, 2026. The reported sale-price ranges were $30.0000 to $30.4300, $30.0100 to $30.9800, and $30.3500 to $31.0400, respectively.

How many KMTS options remained to vest?

The footnotes state that the remaining 33,125 options were vesting in equal monthly installments through March 6, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/29/2026 - 06:47 PM EDT Accepted by SEC EDGAR 10/29/2026 - 06:46 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahboob Vaseem

(Last)

(First)

(Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND

WASHINGTON

98033

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	10/27/2026		M⁽¹⁾		34,809	A	$17	95,418	D
Common Shares	10/27/2026		S⁽¹⁾		34,809	D	$30.0435⁽²⁾	60,609	D
Common Shares	10/28/2026		M⁽¹⁾		39,903	A	$17⁽²⁾	100,512	D
Common Shares	10/28/2026		S⁽¹⁾		39,903	D	$30.4815⁽³⁾	60,609	D
Common Shares	10/29/2026		M⁽¹⁾		4,788	A	$17⁽²⁾	65,397	D
Common Shares	10/29/2026		S⁽¹⁾		4,788	D	$30.5979⁽⁴⁾	60,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options	$17	10/27/2026		M			34,809	⁽⁵⁾	03/06/2035	Common Stock	34,809	$0	124,191	D
Options	$17	10/28/2026		M			39,903	⁽⁶⁾	03/06/2035	Common Stock	39,903	$0	84,288	D
Options	$17	10/29/2026		M			4,788	⁽⁷⁾	03/06/2035	Common Stock	4,788	$0	79,500	D

Explanation of Responses:

1. This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0100 to $30.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.3500 to $31.0400. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

5. Includes 91,066 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

6. Includes 51,163 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

7. Includes 46,375 fully vested options as of the filing date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

	/s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR